fluoxetine has been researched along with warfarin in 27 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (3.70) | 18.7374 |
1990's | 5 (18.52) | 18.2507 |
2000's | 4 (14.81) | 29.6817 |
2010's | 16 (59.26) | 24.3611 |
2020's | 1 (3.70) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Caron, G; Ermondi, G | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Carmichael, R; Lemberger, L; Rowe, H | 1 |
Gibaldi, M | 1 |
Claire, RJ; Cram, DL; Servis, ME | 1 |
Hanger, HC; Thomas, F | 1 |
Brown, PJ; Dewar, MS; Gammack, NS; Woolfrey, S | 1 |
Anderson, ML; Ford, MA; Jaskar, DW; Rindone, JP | 1 |
Brookes, PS; Gray, DA; Karcz, MK; Lopes, CM; Nehrke, KW; Williams, DM; Wojtovich, AP | 1 |
Gorski, JC; Lindamood, C; Ortiz, S; Rackley, R; Shaw, A | 1 |
Donato-Brown, D; Haji Mohd Yasin, NA; Taha, A | 1 |
Aruna Teja, G; Bhaskara Rao, K; Gupta, S; Modukuri, RK; Sashidhara, KV; Shukla, S; Singh, S | 1 |
Ahemad, N; Dong, AN; Ong, CE; Palanisamy, UD; Pan, Y; Yiap, BC | 1 |
2 review(s) available for fluoxetine and warfarin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug interactions: Part I.
Topics: Antidepressive Agents, Tricyclic; Caffeine; Cimetidine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; Fluconazole; Fluoxetine; Hexobarbital; Humans; Ketoconazole; Nimodipine; Oxidoreductases; Pharmaceutical Preparations; Rifampin; Stereoisomerism; Warfarin; Zidovudine | 1992 |
1 trial(s) available for fluoxetine and warfarin
Article | Year |
---|---|
Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Drug Interactions; Fluoxetine; Humans; Hypoprothrombinemias; Middle Aged; Prothrombin Time; Selective Serotonin Reuptake Inhibitors; Warfarin | 1997 |
24 other study(ies) available for fluoxetine and warfarin
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
The effect of fluoxetine on warfarin metabolism in the rat and man.
Topics: Animals; Fluoxetine; Half-Life; Humans; Male; Propylamines; Prothrombin; Rats; Time Factors; Warfarin | 1978 |
Potential interaction between warfarin sodium and fluoxetine.
Topics: Drug Interactions; Ecchymosis; Female; Fluoxetine; Humans; Warfarin | 1991 |
Fluoxetine and warfarin interactions.
Topics: Aged; Drug Interactions; Fluoxetine; Humans; Male; Middle Aged; Warfarin | 1995 |
Fluoxetine-warfarin interaction.
Topics: Blood Coagulation; Drug Interactions; Fluoxetine; Humans; Male; Middle Aged; Warfarin | 1993 |
A novel mitochondrial K(ATP) channel assay.
Topics: Adenosine Triphosphate; Animals; Antidepressive Agents, Second-Generation; Benzothiazoles; Biological Assay; Coumarins; Fluorescent Dyes; Fluoxetine; Glycine; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Kinetics; Male; Mitochondria, Heart; Mitochondrial Swelling; Myocardial Reperfusion Injury; Osmosis; Perfusion; Phosphatidylinositol 4,5-Diphosphate; Potassium; Potassium Channels; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Spectrometry, Fluorescence; Thallium; Uridine Diphosphate | 2010 |
Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies.
Topics: Adult; Antihypertensive Agents; Benzopyrans; Cytochrome P-450 CYP2D6; Digoxin; Drug Interactions; Ethanolamines; Female; Fluoxetine; Furosemide; Genotype; Humans; Hydrochlorothiazide; Losartan; Male; Middle Aged; Nebivolol; Ramipril; Warfarin; Young Adult | 2011 |
Non-traumatic spontaneous spinal subdural haematoma.
Topics: Aged; Antifibrinolytic Agents; Back Pain; Blood Coagulation Factors; Combined Modality Therapy; Decompression, Surgical; Dexamethasone; Early Diagnosis; Early Medical Intervention; Fluoxetine; Glucocorticoids; Hematoma, Subdural, Spinal; Humans; Laminectomy; Magnetic Resonance Imaging; Male; Paraplegia; Spinal Cord Compression; Treatment Outcome; Urinary Retention; Vitamin K; Warfarin | 2012 |
Design and synthesis of new series of coumarin-aminopyran derivatives possessing potential anti-depressant-like activity.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Coumarins; Depression; Dose-Response Relationship, Drug; Drug Design; Fluoxetine; Male; Mice; Models, Molecular; Molecular Structure; Motor Activity; Pyrans; Structure-Activity Relationship; Swimming | 2015 |
The Molecular and Enzyme Kinetic Basis for Altered Activity of Three Cytochrome P450 2C19 Variants Found in the Chinese Population.
Topics: Alleles; Amino Acid Sequence; Asian People; Catalytic Domain; Coumarins; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Fluoxetine; Humans; Ketoconazole; Kinetics; Loratadine; Models, Molecular; Molecular Docking Simulation; Mutagenesis, Site-Directed; Nitriles; Omeprazole; Polymorphism, Genetic; Protein Conformation; Protein Isoforms; Recombinant Proteins; Sertraline; Substrate Specificity | 2020 |